Forget everything you've heard about the benefits of Tamiflu, the Roche corporation's blockbuster influenza drug. A new analysis that includes previously-unpublished trials offers a fresh, and very unflattering, perspective.
More research needs to be done on the companies supplying the vaccines for the troops. They and their well-connected investors are subsidized by the government, which supplies troops for human testing.
Far from being a font of innovation, the drug market has become stagnant. Companies squander a fortune developing "me-too" drugs so they can take out a new patent and receive another avalanche of profits.
Many of us -- patients and physicians alike -- have been thinking about the influenza virus for about a week. Public health officials like the teams at the CDC that I visited yesterday have been thinking about it for years.